COVID-19: characteristics and therapeutics
R Chilamakuri, S Agarwal - Cells, 2021 - mdpi.com
Novel coronavirus (COVID-19 or 2019-nCoV or SARS-CoV-2), which suddenly emerged in
December 2019 is still haunting the entire human race and has affected not only the …
December 2019 is still haunting the entire human race and has affected not only the …
COVID-19 and rheumatoid arthritis crosstalk: emerging association, therapeutic options and challenges
Hyperactivation of immune responses resulting in excessive release of pro-inflammatory
mediators in alveoli/lung structures is the principal pathological feature of coronavirus …
mediators in alveoli/lung structures is the principal pathological feature of coronavirus …
Repurposed antiviral drugs for Covid-19—interim WHO solidarity trial results
WHO Solidarity Trial Consortium - New England journal of …, 2021 - Mass Medical Soc
Abstract Background World Health Organization expert groups recommended mortality trials
of four repurposed antiviral drugs—remdesivir, hydroxychloroquine, lopinavir, and interferon …
of four repurposed antiviral drugs—remdesivir, hydroxychloroquine, lopinavir, and interferon …
Effect of hydroxychloroquine in hospitalized patients with Covid-19
RECOVERY Collaborative Group - New England Journal of …, 2020 - Mass Medical Soc
Background Hydroxychloroquine and chloroquine have been proposed as treatments for
coronavirus disease 2019 (Covid-19) on the basis of in vitro activity and data from …
coronavirus disease 2019 (Covid-19) on the basis of in vitro activity and data from …
Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials
Substantial COVID-19 research investment has been allocated to randomized clinical trials
(RCTs) on hydroxychloroquine/chloroquine, which currently face recruitment challenges or …
(RCTs) on hydroxychloroquine/chloroquine, which currently face recruitment challenges or …
Dexamethasone in hospitalized patients with Covid-19
RECOVERY Collaborative Group - New England Journal of …, 2021 - Mass Medical Soc
Abstract Background Coronavirus disease 2019 (Covid-19) is associated with diffuse lung
damage. Glucocorticoids may modulate inflammation-mediated lung injury and thereby …
damage. Glucocorticoids may modulate inflammation-mediated lung injury and thereby …
Evaluation of the effects of remdesivir and hydroxychloroquine on viral clearance in COVID-19: a randomized trial
A Barratt-Due, IC Olsen… - Annals of internal …, 2021 - acpjournals.org
Background: New treatment modalities are urgently needed for patients with COVID-19. The
World Health Organization (WHO) Solidarity trial showed no effect of remdesivir or …
World Health Organization (WHO) Solidarity trial showed no effect of remdesivir or …
Multilevel engagements of pharmacists during the COVID-19 pandemic: the way forward
Severe acute respiratory syndrome caused by the novel coronavirus (SARS-CoV-2) was first
reported in China in December 2019 which was later declared to be a public health …
reported in China in December 2019 which was later declared to be a public health …
[HTML][HTML] Kidney injury in COVID-19 patients, drug development and their renal complications: Review study
ZM Yarijani, H Najafi - Biomedicine & Pharmacotherapy, 2021 - Elsevier
Since December 2019, the world was encountered a new disease called coronavirus
disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 …
disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 …
A mini-review on the effects of COVID-19 on younger individuals
M Manivannan, MP Jogalekar… - Experimental …, 2021 - journals.sagepub.com
Coronavirus disease 2019 (COVID-19) pandemic has uprooted our lives like never before
since its onset in the late December 2019. The world has seen mounting infections and …
since its onset in the late December 2019. The world has seen mounting infections and …